MYL5: A Protein for Fast and Stable Myosin Regulation (G4636)

Target Name: MYL5

NCBI ID: G4636

MYL5

MYL5: A Protein for Fast and Stable Myosin Regulation

Myosin regulatory light chain 2 (MYL5) is a protein that plays a critical role in muscle contraction and relaxation. It is a member of the myosin regulatory light chain family, which includes several other proteins that regulate myosin ATPase, the protein that powers muscle contraction.

MYL5 is unique because of its rapidity and stability. It is one of the fastest myosin regulatory light chains, with a half-life of only 10 seconds. This rapidity is important for maintaining muscle contractions during intense physical activity. Additionally, MYL5 has a high stability, which allows it to withstand high levels of ATPase activity without breaking down.

MYL5 is also a good biomarker for muscle damage. It is often used to assess the severity of muscle damage caused by exercise, such as muscle pain or muscle injury. This is because MYL5 levels are often elevated in muscle that has been damaged, as a result of the increased energy demand needed to repair the damage.

MYL5 is also a potential drug target. The myosin regulatory light chain family has been shown to be involved in a variety of physiological processes, including muscle contraction and relaxation. As a result, several drugs that target MYL5 have been developed and are currently in use.

One of the most well-known drugs that targets MYL5 is to treat dilated cardiomyopathy (DCM). DCM is a heart condition that is characterized by the thickening of the heart muscle. The myosin regulatory light chain is thought to play a role in the regulation of heart muscle contraction and relaxation, which makes it a potential target for treating DCM.

Another drug that targets MYL5 is used to treat certain types of cancer. The myosin regulatory light chain is known to be involved in cell division and growth, which makes it a potential target for cancer cells. Several anti-cancer drugs that target MYL5 have been developed and are in use.

MYL5 is also a potential target for treating other conditions. For example, it has been shown to be involved in the regulation of skeletal muscle mass and function. This makes it a potential target for diseases that are characterized by muscle loss or dysfunction, such as aging or certain types of muscular dystrophy.

In conclusion, MYL5 is a protein that plays a critical role in muscle contraction and relaxation. Its rapidity and stability make it unique, and its ability to serve as a biomarker and potential drug target make it a valuable tool for the study of muscle physiology and disease. Further research is needed to fully understand the role of MYL5 in muscle physiology and disease.

Protein Name: Myosin Light Chain 5

The "MYL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets